Kala Pharmaceuticals (KALA) Misses Q3 EPS by 126c
Tweet
Share
E-mailGet Alerts KALA Hot Sheet
Join SI Premium – FREE
Kala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($3.41), $1.26 worse than the analyst estimate of ($2.15).
For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CrowdStrike shares jump on earnings beat, raised outlook
- Okta, Inc. (OKTA) Tops Q2 EPS by 8c; offers guidance
- Synopsys (SNPS) Tops Q3 EPS by 24c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
